Biotech · Public company · San Diego, CA, US
Viking Therapeutics, Inc.
Ticker VKTX · SEC CIK 0001607678
Track this companyFree. Adds Viking Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials104 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline7
- VK2735Phase 3 · Weight LossClinicalTrials.gov · fetched Nov 12, 2026
- VK2809Phase 2 · HyperlipidemiaClinicalTrials.gov · fetched Nov 12, 2026
- VK2809Phase 2 · NASH - Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- VK5211Phase 2 · Hip FracturesClinicalTrials.gov · fetched Nov 12, 2026
- SC VK3019Phase 1 · Obese AdultsClinicalTrials.gov · fetched Nov 12, 2026
- VK0214Phase 1 · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)ClinicalTrials.gov · fetched Nov 12, 2026
- VK2735 DrugPhase 1 · Obese AdultsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Phase 1 Study of VK3019 in Overweight and Obese Adults Without ComorbiditiesPHASE1 · RECRUITING · started Jul 6, 2026ClinicalTrials.gov NCT07846033 · fetched Nov 12, 2026
- A Phase 1 Study of VK2735 in Obese Adults Without ComorbiditiesPHASE1 · RECRUITING · started Nov 18, 2025ClinicalTrials.gov NCT07838740 · fetched Nov 12, 2026
- VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 23, 2025ClinicalTrials.gov NCT07104383 · fetched Nov 12, 2026
- VK2735 for Weight Management Phase 3PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 23, 2025ClinicalTrials.gov NCT07104500 · fetched Nov 12, 2026
- VK2735 for Weight Management Phase 2 (Venture Oral Dosing)PHASE2 · COMPLETED · started Dec 18, 2024ClinicalTrials.gov NCT06828055 · fetched Nov 12, 2026
- VK2735 for Weight Management Phase 2PHASE2 · COMPLETED · started Aug 31, 2023ClinicalTrials.gov NCT06068946 · fetched Nov 12, 2026
- A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMNPHASE1 · COMPLETED · started Jun 22, 2021ClinicalTrials.gov NCT04973657 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASHPHASE2 · COMPLETED · started Nov 15, 2019ClinicalTrials.gov NCT04173065 · fetched Nov 12, 2026
- Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver DiseasePHASE2 · COMPLETED · started Sep 28, 2016ClinicalTrials.gov NCT02927184 · fetched Nov 12, 2026
- Acute Hip Fracture Study in Patients 65 Years or GreaterPHASE2 · COMPLETED · started Oct 30, 2015ClinicalTrials.gov NCT02578095 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Oct 23, 2025 · fetched Nov 12, 2026